Puma Biotechnology (NASDAQ:PBYI) issued its quarterly earnings data on Monday. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by $0.39, StockRatingsNetwork reports.
Puma Biotechnology (NASDAQ:PBYI) traded up 0.35% on Monday, hitting $243.33. The stock had a trading volume of 223,799 shares. Puma Biotechnology has a 52-week low of $33.70 and a 52-week high of $244.38. The stock has a 50-day moving average of $123.2 and a 200-day moving average of $101.3. The company’s market cap is $7.328 billion.
PBYI has been the subject of a number of recent research reports. Analysts at Citigroup Inc. raised their price target on shares of Puma Biotechnology from $99.00 to $292.00 in a research note on Wednesday, July 23rd. They now have a “buy” rating on the stock. On a related note, analysts at Leerink Swann raised their price target on shares of Puma Biotechnology from $144.00 to $300.00 in a research note on Wednesday, July 23rd. They now have an “outperform” rating on the stock.
Puma Biotechnology, Inc is a development-stage biopharmaceutical company that acquires and develops products for the treatment of various forms of cancer.
Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.